Growth within each of 2010's major financial indicators outpaced 2009's growth rates.
Publicly traded medtech companies in the US and Europe turned in a solid performance in 2010.
Financial outlook for medtech
Revenue growth was led in large part by conglomerates that rebounded after declining in 2009.
Growth within each of 2010's major financial indicators outpaced 2009's growth rates.
Medical technology at a glance, 2010
(US$b, data for non-conglomerates except where indicated)
| Public company data | 2010 | 2009 | % change |
| Revenues | $315.9 | $303.6 | 4% |
| Conglomerates | $122.3 | $116.5 | 5% |
| Non-conglomerates | $193.7 | $187.1 | 4% |
| R&D expense | $12.4 | $11.61 | 7% |
| Net income | $17.4 | $12.2 | 43% |
Cash and cash equivalents
and short-term investments | $42.0 | $35.8 | 17% |
| Number of employees | 764,355 | 739,531 | 3% |
| Number of public companies | 436 | 443 | -2% |
Source: Ernst & Young and Capital IQ
Data shown for US and European public companies.
Looking ahead, the industry continues to grapple with mounting pressures and faces considerable uncertainty due to global economic events.
Yet, several factors may positively effect medtech's long term growth.
- Further expansion into emerging and underserved markets
- Aging Western populations
- Longer life expectancies
- A gradual improvement in the global economy
However, to sustain growth in the immediate future, companies will need to address the pressures listed above.
<< Previous | Next >>
